Nonalcoholic Fatty Liver Disease-Associated Liver Fibrosis Is Linked with the Severity of Coronary Artery Disease Mediated by Systemic Inflammation

Abstract

Background and Aim. Nonalcoholic fatty liver disease (NAFLD) is an independent risk factor for cardiovascular disease. Hepatic fibrosis is the most significant determinant of all-cause- and liver -related mortality in NAFLD. However, the relationship between NAFLD fibrosis and severe coronary artery disease (CAD) remains unclear. Methods and Results. We conducted a retrospective study of 531 patients with ultrasonogram-confirmed NAFLD who underwent percutaneous coronary intervention (PCI). Then, all patients were separated into four categories by Gensini score (0, 0-9, 9-48, and ≥48) for use in ordinal logistic regression analysis to determine whether NAFLD fibrosis was associated with increased Gensini scores. Mediation analysis was used to investigate whether systemic inflammation is a mediating factor in the association between NAFLD fibrosis and CAD severity. FIB − 4 > 2.67 ( OR = 5.67 , 95% CI 2.59-12.38) and APRI > 1.5 ( OR = 14.8 , 95% CI 3.24-67.60) remained to be independent risk factors for the severity of CAD after adjusting for conventional risk factors, whereas among the inflammation markers, only neutrophils and neutrophil-to-lymphocyte ratio (NLR) were independently associated with CAD. Multivariable ordinal regression analysis suggested that increasing Gensini score (0, 0-9, 9-48, and ≥48) was associated with advanced NAFLD fibrosis. ROC curve showed that either fibrosis markers or inflammation markers, integrating with traditional risk factors, could increase the predictive capacity for determining CAD. Inflammation markers, especially neutrophils and NLR, were mediators of the relationship between NAFLD fibrosis and CAD severity. Conclusions. NAFLD patients with advanced fibrosis are at a high risk of severe coronary artery stenosis, and inflammation might mediate the association between NAFLD fibrosis and CAD severity.

Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis

“…(a) fast decongestion, which may cause an immediate reduction in HHF, and/or (b) a high FIB-4 score associated with NAFLD may also be a reflection of systemic inflammation, fibrosis and associated CVDs. 47 Preclinical animal model data for finerenone showed anti-inflammatory and antifibrotic effects, 48 and although the clinical translation may be complex, the systemic antifibrotic effects may be effective in the long-term, particularly in patients with elevated fibrosis markers. Moreover, finerenone has fewer side effects compared with other MRA antagonists.…”

Lowering n-6/n-3 Ratio as an Important Dietary Intervention to Prevent LPS-Inducible Dyslipidemia and Hepatic Abnormalities in ob/ob Mice

“…Dyslipidemia is a strong pathological consequence of inflammatory responses in the hepatic pathologies associated with MetS [ 60 , 61 , 62 ]. NAFLD is a type of steatosis, where >5% ectopic fat accumulates in the liver in the absence of competing etiologies such as heavy alcohol use.…”

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease

“…Several studies have found that high FS associates with incidence of coronary heart disease [ 31 , 32 ] as well as the angiographic complexity [33] , [34] , [35] , risk of MACE [ 34 , 36 ], and death [37] in patients with established coronary heart disease. In an analysis of the IMPROVE-IT trial that compared ezetimibe with placebo in patients with ACS treated with simvastatin [36] , high FS (>0.67, n=2,106) vs low FS (<-1.455, n=5,440) was associated with 30% increased risk of MACE.…”